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Treatment-induced Brain Plasticity in Borderline Personality Disorder: 
review of fMRI studies  
 
 
Maria Uscinska, Ph.D, Silvio Bellino, M.D. 





Whilst neural substrates of symptoms expression in Borderline Personality Disorder (BPD) have 
been studied extensively, neural mechanisms mediating post treatment amelioration of symptoms 
remain poorly characterized.  Herein present review sheds a critical light on all here-to-date fMRI 
findings of brain changes in BPD patients following a treatment with psychotherapy or drugs. 
Preliminary evidence points to downregulation of neuronal activity within the insula and amygdala, together 
with differential employment of prefrontal areas, mainly orbitofrontal cortex (OFC), anterior cingulate cortex 
(ACC) and dorsolateral prefrontal cortex (dlPFC), as well as enhanced functional connectivity between limbic 
and prefrontal regions induced by DBT.  Identifying neural circuits behind treatment processes may 
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Introduction     
 
Beyond delineating biomarkers of psychiatric disorders, novel neuroimaging techniques are used to 
provide neural parameters of therapeutic change, by measuring brain changes induced by specific 
modes of therapy.  Understanding how various treatments achieve their therapeutic effects on the 
level of cerebral reorganization of specific circuits holds promise for more refined approaches to 
target more specific neuropathology.   
 
Neuroimaging literature has recently begun to address neural mechanisms driving cerebral 
reorganization of specific circuits linked to post treatment amelioration of symptoms in patients with 
Borderline Personality Disorder (BPD).  This severe psychiatric disorder is characterized by a 
pervasive pattern of instability in affect regulation, impulse control, self-image, cognition and 
interpersonal relationships [1].  The severity and morbidity of the disorder is associated with frequent 
self-damaging and impulsive behaviors, such as suicide, self-harm, or substance abuse [2,3].  Factor 
analysis and neurobiological studies have organized BPD symptoms around three domains of 
dysfunction, namely affective dysregulation, behavioural dysregulation (impulsivity) and disturbed 
relatedness [4].  While disturbance in interpersonal relations is characteristic of disordered 
personality in general, ‘disturbed relatedness’ was proposed to best describe the interpersonal style in 
BPD, uniquely characterized by turbulence and excessive fear of abandonment, presumably resulting 
from impaired mentalization capabilities and marked rejection sensitivity [5].  Since core domains of 
pathology are expressed to varying degrees in every patient and the diagnosis requires five out of 
nine criteria, the population of BPD patients results in abundant clinical variability.  This contributes 
to the existing controversy over the treatment of BPD in terms of assigning patients on the basis of 
the diagnosis to one from a list of treatments that have shown superiority over treatment as usual 
[6,7].  Thus, identifying neural mechanisms behind treatment processes may tap into the patient 
heterogeneity disguised by the BPD diagnosis, and lead to a greater sophistication in matching of 
patients to specific interventions. 
 
1) The Biological Basis of Borderline Personality Disorder 
 
In neural terms the complexity of BPD is best understood as subtle deficits in multiple networks.  
Disturbances in the processing and regulation of emotions, characterized by aberrant variability in 
affective states and frequent negative emotions in response to seemingly neutral stimuli [for a review 
see ref. 8] are believed to constitute the core of borderline pathology [9, 2005p.372].  Studies probing 
emotional and cognitive processing in BPD have identified abnormal top-down processes, 
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characterized by dampened activity in prefrontal cortex (PFC) coupled with abnormal bottom- up 
emotion generation reflected in enhanced activity within limbic structures [for a review see ref. 10].   
Growing body of neuroimaging data have highlighted hyperactivity in the amygdala [11-13] and 
insula [13] in the context of emotional stimuli, together with reduced activity in the ACC, OFC and 
frontopolar cortex (FPC).  These findings led to assumptions of diminished recruitment of frontal 
brain regions involved in regulatory and inhibitory processes over enhanced limbic activity in 
emotional contexts [14, 15].  Whilst feelings of emptiness, dissociation, identity and interpersonal 
disturbances were found to be directly related to affective instability [16], self-injury is hypothesized 
to represent efficient, yet highly dysfunctional attempt to regulate disturbed emotions [17] based on 
deactivation of the amygdala [10] and lower posterior cingulate cortex (PCC) connectivity with the 
dlPFC by experimentally induced pain in BPD [18].  Moreover, impaired affect regulation may 
translate into perception bias while appraising social stimuli and thus contribute to difficulties in 
interpersonal functioning [see ref. 19 for a review, 20].           
Studies of impulsivity in BPD involve scanning patients during holding or suppression of an already 
selected or initiated response and thus late control processes [21].  Stop-signal and Go/NoGo 
paradigms are the main behavioural inhibition tasks used to probe clinically salient interaction of 
negative affective processing and inhibitory control [22, 23].  Deficits in the recruitment of specific 
frontolimbic neural substrates providing control or ‘brakes’ for excessive bottom-up activity within 
limbic regions in the presence of negative emotional stimuli [24] and stress [25] have been identified.   
While healthy subjects selectively activated the posterior-medial OFC, dorsal ACC, dlPFC, amygdala 
and hippocampus in inhibitory control, BPD patients exhibited dysfunction in the posterior-medial 
OFC and the dorsal and subgenual ACC.  Silbersweig et al. [13] provided further support for the 
model of impaired prefrontal inhibitory function in BPD patients in the context of negative emotions 
during a task requiring motor inhibition.  Reported decreased activity in ventromedial PFC (including 
medial OFC and subgenual ACC), and elevated extended amygdalar ventral striatal activity was 
found to correlate with decreased constraint and increased negative emotion, respectively.  
Functional neuroimaging of social cognition has started to elucidate possible cerebral substrates of 
emotional and behavioural facets in BPD contributing to impaired functioning in interpersonal 
context.  ‘Interpersonal hypersensitivity’ have been proposed as the most prominent characteristic 
exacerbating interpersonal disturbances in BPD.  It is associated with perceptions of others 
selectively biased toward negative emotions and attributes evidenced in the tendency to ascribe anger 
to ambiguous expressions (for a review see ref. 19), and to perceive others’ faces as untrustworthy, 
relative to healthy controls [26].  Neuroimaging data have identified increased and prolonged 
amygdala responses [27, 28], and elevated activity in the anterior insula [29, 30] as neural substrates 
of interpersonal hypersensitivity, which led to assumptions of enhanced bottom-up emotion 
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generation processes [31].  The silence network which gives a stimulus the capacity to be favoured in 
early bottom-up evaluation processes for valence and salience appears to be mediated by functional 
coupling between the ACC and the amygdala, together with the anterior insula [32].  
Since appraisal of others as threatening, deceitful and untrustworthy is likely to lead to poor social 
reward experience, alterations in mesolimbic circuitry have been proposed as the disturbed circuitry 
contributing to difficulties in interpersonal functioning in BPD.  In particular, affected individuals are 
highly sensitive to threat of social rejection, negative judgement, unfairness, and exhibit general 
mistrust of others [26, 33- 38].  Indeed, mistrust and deficient cooperation constitute the core of 
borderline pathology, and are believed to reflect an insecure attachment style [39].  Furthermore, 
rejection sensitivity was found to mediate bias toward untrustworthy attributes of others and 
borderline traits [26, 37].  In neural terms, alterations in brain reward system activation including the 
pregenual ACC, ventral tegmental area and ventral striatum in response to social stimuli have been 
identified [40].  These results were interpreted as an evidence for a deficit in differentiation between 
reward and non-reward anticipation.  In addition, trust game revealed that cooperation in BPD 
patients tended to decrease over time, presumably due to difficulties in perceiving the violation of 
social norms [36].  While healthy controls exhibited activation of the insula depending on the fairness 
of the transaction, in BPD individuals it was hyperactive during the whole experiment.  Given that 
insula plays an important role in the processing of social stimuli and detection of unfairness [41], its 
hyperactivity in individuals with BPD may account for some of the difficulties in social interactions.   
Deficit in mentalization, that is inability to represent one’s own and other people’s mental states is 
consistently reported in affective theory of mind/cognitive empathy tasks [see ref. 42, 43 for a 
review], and seems to be mediated by overactive or poorly regulated amygdala.  Neuroimaging data 
have highlighted reduced activity in the superior temporal gyrus and sulcus during cognitive empathy 
task, as well as elevated activation of amygdala and somatosensory cortex during affective empathy 
in BPD patients relative to healthy controls [44-46]. 
The frontolimbic deficit was echoed in a recent meta- analysis, which highlighted elevated activity in 
amygdala-hippocampal and posterior cingulate cortex, and decreased bilateral dlPFC activation in 
response to negative versus neutral stimuli in BPD patients relative to healthy participants [47]. 
Moreover, the interplay between dlPFC and hippocampus was found to be deeply involved emotional 
and behavioural control in BPD [14, 15, 48, 49].  Interestingly, prior meta-analysis on neural 
correlates of emotion dysregulation yielded similar results, however, limbic hyperactivity was only 
seen in unmedicated patients, which demonstrates that sample characteristics may account for 




2) What works in BPD treatment 
 
Once deemed untreatable, today BPD patients have a more optimistic outlook on treatment with 
various psychotherapies and drug interventions.  The gold standard of care recommends 
psychotherapy integrated with pharmacotherapy, wherein each modality targets specific domains of 
pathology [51].  The combined treatment approach has embraced the distinction between 
temperament and character proposed by the psychobiological model of personality disorders [52], 
which continuous to inform effective treatment planning.  It identifies four dimensions which make 
up the temperament construct, namely novelty seeking, harm avoidance, reward dependence and 
persistence; and three dimensions of character including self- transcendence, self- directedness, and 
cooperativeness.  Whilst temperament manifests itself early in life, tends to be highly stable over 
time, and is deemed responsive to pharmacotherapy, the latter is malleable, develops throughout 
adulthood, and is therefore amenable to treatment with psychotherapy.  In this view, a patient 
manifesting impulsivity and affect dysregulation is a candidate for a treatment with medications, such 
as the selective serotonin re-uptake inhibitors (SSRIs), whereas low scores in self- directedness and 
cooperativeness for instance, are targeted with an appropriate psychotherapy.   
 
2.1) Psychosocial treatments for BPD 
 
Variety of psychotherapeutic approaches have been designed specifically for BPD, and five 
established as evidence based treatment, namely Dialectic Behavioral therapy (DBT), Mentalization- 
Based treatment (MBT), Transference- Focus psychotherapy (TFP), Schema- Focused therapy (SFT) 
and systems training for emotional predictability and problem solving (STEPPS) [53].  DBT and 
MBT are the most researched, refined and widely adopted approaches with the largest evidence base 
for BPD treatment [54-58].   
 
DBT was developed for suicidal patients based on BPD deficit model in self-regulation, distress 
tolerance and interpersonal skills, believed to arise from transaction between highly sensitive 
individuals and environments invalidating of their vulnerabilities [54-56].  In this view, incorporating 
the strategy of validation with the concept of dialectics, DBT focuses on skills acquisition and 
behavioural shaping to enable patients to become more mindful and to manage their emotions and 
relationships more effectively.  Therein lies the mechanism of change.  
 
Rooted in attachment and cognitive theory, MBT proposes a borderline pathology model based on 
mentalization deficit, reflected in inability to comprehend own and others’ states of mind [57,58].  
Instability in emotions and relationships is claimed to develop in constitutionally vulnerable 
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individuals [59] subjected to early trauma, neglect and inadequate mirroring of emotions by the 
caregiver [60].  Thus the aim of MBT is to foster the capacity to mentalize in the context of 
attachment relationships, which constitutes the essence of the mechanism of change.  Therapy-
induced neural recovery from BPD is theorized to be mediated by enhanced control of 
neuropsychological systems behind the organization of interpersonal relationships [58].  
 
 
2.2) Pharmacotherapy for BPD 
 
Despite overwhelming number of drug efficacy studies for BPD, due to methodological issues in the 
evidence base, pharmacotherapy remains off-label with no Food and Drug Administration (FDA) nor 
European Medicines Agency (EMA) approved medications for the disorder.  Nevertheless, the 
official treatment guidelines state that pharmacotherapy is an important adjunct used to treat well 
defined target symptoms, which tend to fall within three behavioural dimensions, namely affective 
dysregulation, impulsive behavioural dyscontrol, and cognitive perceptual distortion [61,62].  A 
recent review supported the efficacy of SSRIs, in particular fluoxetine for impulsivity and affective 
symptoms; mood stabilizers among which valproate, topiramate, and lamotrigine demonstrated 
efficacy for affective symptoms related to anger and impulsive aggression; olanzapine was the most 
efficacious among second generation antipsychotics in targeting aggressiveness, affective and 
cognitive-perceptual symptoms [63].  Furthermore, recent efficacy studies point to novel drugs, such 
as opioid antagonist [64,65], clonidine [66,67], omega- 3 fatty acids [68-70], and oxytocin [71-73] in 
reducing affective instability, impulsivity, self - injuries, and dissociative symptoms.  Fundamentally, 
the abundance of options with poorly specified benefits have encouraged polypharmacy, which 
sometimes leads to undesirable side effects [74].  
While traditional pharmacotherapies for BPD target primarily the serotonergic and dopaminergic 
systems subserving domains of impulsive aggression and affective dysregulation, symptoms 
associated with interpersonal problems, such as chronic feelings of emptiness, identity disturbance 
and abandonment seem unresponsive to available pharmacotherapies [75].  The need to develop 
neurobiologically informed specific medication for these symptoms was encouraged by the theory of 
altered regulation within the OXT system as the underlying mechanism of interpersonal disturbances 
in BPD [76].  To date, studies involving healthy and clinical subjects have implicated the OXT 
system in certain abnormalities in behavioural mechanism closely related to interpersonal 
disturbances, hence supporting the therapeutic potential of OXT for this domain of pathology.  A 
conceptual framework of mechanisms modulated by OXT was developed including the following: 
the brain silence network of interpersonal hypersensitivity; the affect regulation circuit regulating 
top-down processes; the mesolimbic circuit mediating social reward; and brain regions mediating 
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cognitive and emotional empathy [77].  It is further claimed that the role of OXT may not be specific 
to borderline pathology, but rather a host of psychiatric conditions were parent-child attachment have 
been disrupted [78,79].  Whilst evidence for prosocial effects of this neuropeptide in healthy and 
clinical subjects appear promising, conclusions with regard to BPD are hampered by insufficient 
research and methodological issues.  A recent review of 5 clinical trials of intranasal OXT effects on 
social cognition in BPD provided conflicting results reflected in attenuated emotional responses to 
stress as well as worsened interpersonal anxiety and decreased cooperative behaviour [80].  Thus, 
further research is warranted to reconcile mixed results and to answer the remaining questions on the 
use of OXT in BPD treatment.  
3) Review of fMRI studies on treatment-induced brain plasticity  
 
While clinical benefits of available treatments for BPD have been extensively researched, whether 
amelioration of symptoms translates into changes in cerebral organization within specific circuits is 
yet to be established.  With this in mind, eight studies of treatment- induced brain plasticity were 
identified, six focusing on Dialectical Behavioural Therapy (DBT), one on Transference-Focused 
psychotherapy (TFP), and one on Oxytocin (OXT) (see Table 1).  Identified publications were 
discussed, and important issues summarized for consideration in future research. 
 
Table 1 Neurofunctional changes in the brain associated with treatment models for BPD 
 Sample(treatment 
responders) 
                      Intervention            Study design                            Main findings                                 
Author  BPD  HC CC    treatment control Target  Task   Design Treatment-induced neural 
changes   
   Conclusions  
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*The table shows fMRI studies of neural mechanisms mediating post treatment amelioration of BPD 
symptoms following psychosocial treatments and Oxytocin. 
 
3.1) fMRI studies of DBT-induced brain changes  
 
To date, six fMRI studies have examined neurofunctional changes under DBT in BPD subjects.  Two 
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early pilot studies set out to establish whether DBT- induced improvement in regulation of affective 
arousal in BPD patients was mediated by alterations in underlying cerebral networks.  In the first 
study [81] six unmedicated female BPD patients matched against six healthy controls were scanned 
five times before, during and after a 12-week in-patient treatment program while viewing the 
International Affective Picture System [82].  Functional changes in four treatment responders 
revealed neural changes in limbic and cortical regions, including decreased activity in ACC, PCC, 
insula, left amygdala and both hippocampi to aversive stimuli relative to controls.  The most striking 
difference between groups was evident in reduced activation in the caudal ACC in BPD patients.  
Although the study succeeded in highlighting the role of amygdala normalization consistent with 
psychotherapy effects in other mental disorders [83-85], it has to be interpreted with caution as the 
response criteria dividing patients into responders and non-responders were defined by meeting two 
or three treatment objectives rather than standardized instruments.  This limitation was addressed by 
Goodman [86] who examined the effect of 12-month course of DBT on amygdala activity and 
overall emotion regulation, as measured by changes in the Difficulties in Emotion Regulation Scale 
(DERS) [87].  Unmedicated BPD outpatients matched to healthy controls were pre- and post- DBT 
treatment scanned.  They exhibited significant reduction in overall amygdala activation, which was 
particularly notable in the left hemisphere and during repeated- emotional pictures.  Furthermore, 
attenuated activity in the amygdala to repeated unpleasant pictures was associated with an 
improvement in overall emotion regulation (DERS).  Thus, the notion that DBT targets amygdala 
hyperactivity in BPD was supported, however, the pilot nature of both studies, a small sample size 
and limited statistical power render results preliminary.  Finally, aforementioned studies did not 
include a clinical control group and therefore borderline- specific conclusions cannot be made.  
Two following studies focused on DBT associated changes in neural correlates of various emotion 
regulation strategies and related symptom characteristics.  Schmitt et al. [88] set out to investigate the 
effect of a 12-week inpatient DBT program on neural correlates of reappraisal in 32 female DBT 
patients, compared to 24 healthy control participants, and a clinical control group of 16 BPD patients.  
Participants received either constant medication (54.2%) or no medication (45.8%) during the study 
period.  Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) [89] was used to 
determine treatment response, and 17 identified responders were compared against the clinical 
control group.  Participants were scanned before and after a DBT program while performing a 
reappraisal task [90].  The study revealed post- treatment reduction in the insula and ACC activity, 
with increased connectivity of ACC to medial and superior frontal gyrus, superior temporal gyrus 
and inferior parietal cortices.  Thus, treatment response was associated with attenuated activation in 
the amygdala, ACC, OFC, and dlPFC, with elevated connectivity within a limbic-prefrontal network 
during the reappraisal of negative stimuli after DBT.  Similarly, Winter et al. [91] investigated 
whether neural correlates of distraction might change with a successful DBT.  It was hypothesized 
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that after the treatment patients would exhibit stronger use of a fronto-parietal emotion regulation 
network and attenuated limbic hyper-reactivity during a distraction task.  31 BPD patients under 
constant medication at each fMRI measurement were scanned before and after a 12- week 
residential DBT-based treatment during a distraction task.  They were compared to 15 BPD control 
patients, either under non-DBT-based treatment or no treatment at all, and 22 healthy participants. 
When compared to both control groups, 16 DBT responders exhibited attenuated activity in the 
right inferior parietal lobe/supramarginal gyrus during distraction from negative rather than neutral 
stimuli, which was correlated with improvement in self-reported borderline symptom severity 
(ZAN-BPD).  They also evidenced reduction in the right perigenual ACC activity and increased 
activity in these regions during distraction in the context of aversive stimuli. Thus, post- DBT 
changes in neural activity associated with distraction were interpreted as a shift from emotional to 
more cognitive processing during viewing aversive stimuli, which suggests a lower emotional 
susceptibility during distraction after successful DBT. Even if the percentage of medicated 
individuals did not differ between BPD groups, they received combinations of drug subtypes making 
it impossible to isolate the effect of a single agent.  As previously established, drugs may attenuate 
emotional responses in BPD patients [47].   
New insight into the effect of DBT on pain perception and neural processing of pain in BPD was 
provided by Niedtfeld et al. [92], who investigated whether neural mechanism driving the role of 
pain in emotion regulation in BPD could be normalized under the treatment.  Changes in pain 
threshold or appraisal of pain under 12-week inpatient DBT program were examined in 28 female 
BPD patients, compared to 15 patients with treatment as usual, and 23 healthy control  subjects.  
They were fMRI scanned before and after treatment, pairing the presentation of picture stimuli 
eliciting negative emotions (IAPS, EPS) with thermal stimuli inducing heat pain, in order to 
establish the role of pain in emotion regulation.  Treatment response was assessed resulting in 13 
responders and 15 non-responders using reliable change index [93].  Results revealed pretreatment 
amygdala deactivation in response to painful stimuli, and altered connectivity between left 
amygdala and dorsal ACC in BPD patients.  Following DBT these changes reduced as compared 
with patients under treatment as usual with no observed differences in pain thresholds between 
patient groups.  Although the study succeeded in demonstrating that neural pain processing in BPD 
tended to normalize with DBT, presumably due to treatment-induced increased functional emotion 
regulation, firm conclusions cannot be drawn.  The study is limited by low statistical power, flawed 
by employing self- selection process in assigning patients to DBT treatment, and the use self-rating 
scale to measure pain. 
While aforementioned studies focused on neural changes mediating amelioration in affective 
regulation, one study examined pre-and- post DBT activation in PFC during impulse control in self- 
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harming BPD patients as a potential predictor of treatment outcomes [94].  Since DBT targets deficits 
in response inhibition considered to underlie self-harm [95,96], it was investigated whether patterns 
of activation in neural correlates of target deficits may isolate markers of treatment response and 
attrition.  In this view, 29 actively self-harming BPD patients (90.30% females) completed functional 
near-infrared spectroscopy (fNIRS) neuroimaging procedures prior to and after 7 months of DBT.  
The Scarborough Non-Affective Go/No-go Task was used to measure motor inhibitory control, 
known to probe bilateral medial and inferior frontal gyri during response inhibition [97].  Patients 
who benefited most from the treatment in terms of reduced incidence of self- harm exhibited 
attenuated levels of activity in dlPFC before therapy, and were characterized by the highest increases 
in activity in this region after 7 months of treatment.  In addition, increases in the right dlPFC activity 
was associated with lesser incidence of self-harm, even when improvements in BPD symptoms 
severity, depression and mania were accounted for.  Five patients who did not complete the treatment 
demonstrated greater pre-treatment activation in the medial PFC and right inferior frontal gyrus 
compared to treatment-completers, which is likely to reflect a lesser recruitment by the PFC of 
inhibitory control processes.  Thus, the study put forward the notion that pre-treatment patterns of 
neural activity in areas of the PFC mediating impulse control in BPD patients may be associated with 
treatment responses to DBT and attrition from therapy.   
 
3.2) fMRI study of TFP-induced brain changes  
With regard to psychodynamically oriented therapy, only one pilot study examined TFP-induced 
alterations in frontolimbic neural activation behind symptom amelioration in domains of constraint, 
affective liability and aggression, as well as predictors of treatment response in BPD [98].  Ten 
diagnosed females were pre- and post-treatment scanned 10-14 months apart while performing 
emotional-linguistic go/no-go paradigm [99].  Some of them had comorbid panic disorder, phobia, 
generalized anxiety disorder, alcohol and substance abuse, as well as diagnoses of personality 
disorders.  Moreover, five patients reported to be on psychotropic medication during the study 
period.  Results revealed post -TFP relative increase in activation within dorsal prefrontal areas 
(dorsal anterior cingulate, dorsolateral prefrontal, and frontopolar cortices), and relative decrease in 
activation within ventrolateral PFC and the hippocampus.  Furthermore, amelioration in constraint 
and affective lability were positively correlated with relative increase in activation of the left dorsal 
ACC and left posterior-medial OFC/ventral striatum activation, respectively.  In addition, 
improvement in affective liability was negatively correlated with activation in the right 
amygdala/parahippocampal. With regard to predictors of treatment outcomes, pre- TFP 
hypoactivation in the right dorsal ACC was associated with post- treatment improvements in 
constraint, whereas pre-treatment hypoactivation in the left posterior-medial OFC/ventral striatum 
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hypoactivation predicted amelioration in affective lability.  These preliminary findings provided the 
first account of alterations in frontolimbic circuitry induced by a psychodynamically oriented 
psychotherapy.  
3.3) fMRI studies of oxytocin-induced brain changes  
Given that OXT was previously shown to optimize reflexive processing of social cues and modulate 
the salience of social information by attenuating amygdala activity, one study investigated its effect 
on facial threat processing in BPD, typically characterized by hypersensitivity and the tendency to 
disambiguate neutral into angry expressions [100].  Patterns of amygdala activity in response to 
angry and fearful compared with happy facial expressions were scanned in 40 nonmedicated BPD 
female patients and 41 healthy women during emotion classification task 45 minutes after intranasal 
administration of 26 IU of oxytocin or placebo.  Eye tracking combined with fMRI scans revealed 
post-OXT reduction in posterior amygdala hyperactivation associated with reduced attentional bias 
toward socially threatening cues in BPD females.  The strongest effects were observed in the 
posterior part of the amygdala, presumably corresponding to the basal nucleus involved in assigning 
salience to negative facial expressions and in redirecting attention toward socially pertinent locations 
within visual field [101,102].  Thus, the study shed initial light on down-regulation of social salience 
by intranasal administration of OXT in BPD, which may help to reduce stress reactivity and improve 
threat-driven reactive aggression in the disorder.  However, as no clinical control group was included 
in the study, caution must be exercised while drawing borderline- specific conclusions.  
 
Discussion 
First and foremost, preliminary evidence supports that DBT achieves its therapeutic effect on 
emotion regulation through changes in limbic and cortical networks [81, 94], which further advances 
the thesis that the treatment targets frontolimbic imbalances as part of the disturbed circuitry [10].  
Patterns of decreased activity in ACC, PCC, insula, left amygdala and in both hippocampi to aversive 
stimuli supported the role of amygdala normalization, which is consistent with psychotherapy effects 
in other mental disorders [82-84].  Importantly, reduction in the caudal ACC in the target group 
points to a more efficient use of cognitive strategies to attenuate adverse feelings [11], hence may 
indicate biological underpinnings behind therapeutic processes of affective dysregulation.  Treatment 
effects were particularly notable in the left hemisphere, which was associated with an improvement 
in overall emotion regulation (DERS).  
Consistent with skills deficit model of BPD, gathered evidence supports that acquisition of affective 
control strategies under DBT translates into alteration within underlying neural substrates of emotion 
regulation.  Although skills training is the main focus of the therapy, only two studies have 
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investigated pre-and-post DBT alteration in underlying brain activity pattern.  Schmitt et al. [88] 
demonstrated that improved cognitive reappraisal after 12-week inpatient program was associated 
with dampened insula and ACC activity, coupled with enhanced connectivity of the latter to medial 
and superior frontal gyrus, superior temporal gyrus, and inferior parietal cortices. Furthermore, post-
treatment increase in dorsal ACC activity during exposure to negative stimuli was associated with 
improvement self-reported BPD symptoms, thus elucidating possible neural marker of improved 
emotion control.  These findings build on prior knowledge of reduced prefrontal-limbic connectivity 
and the role of prefrontal limbic regions in successful emotion control in BPD [18].  Thus, rethinking 
feelings mediated by quieting of amygdala, ACC, OFC, and dlPFC, as well as enhanced limbic-
prefrontal network connectivity, appears to be effective in reducing BPD symptomatology.   
In addition, successful DBT may trigger adaptive changes in neural correlates of distraction (91). 
This was reflected in post-treatment reduction in the right perigenual ACC activity and increased 
activity in these regions during a distraction task in the context of aversive stimuli.  Furthermore, 
attenuated activity in the right inferior parietal lobe/supramarginal gyrus during distraction from 
negative stimuli was found to be correlated with improvement in self-reported borderline 
symptoms.  These alterations in activity patterns indicate a shift from emotional to more cognitive 
processing in the presence of aversive stimuli, which may suggest a lower emotional susceptibility 
after successful DBT.  Interestingly, reduced limbic hyper-reactivity during distraction not 
associated with BPD symptom improvement supports the notion of distraction being an automatized 
and overlearned emotion regulation strategy [103], which attenuates limbic reactivity to aversive 
stimuli independent of symptom severity.  Although results complement prior findings of elevated 
insular and limbic responding associated with disturbed fronto-parietal, inhibitory functioning in 
BPD patients during distraction from negative stimuli, caution must be exercised while interpreting 
both studies as patients were not medication- free.   
Initial evidence exists to suggest that providing adaptive emotion regulation techniques under DBT 
may reduce the soothing effect of pain on emotional arousal at the neural level [92].  While pre-
treatment application of painful stimuli to BPD patients triggered amygdala deactivation together 
with altered connectivity between left amygdala and dlPFC, thus confirming the role of pain in 
emotion regulation, these activity patterns tended to normalize with treatment.  Also, the thesis that 
DBT targets deficits in response inhibition underlying self-harm was supported by evidence of post-
treatment increase in right dlPFC activity associated with reduction in self-harm [94].  In addition, 
treatment responders evidenced lower pre- treatment levels of neural activation in the dlPFC, 
whereas treatment attrition was predicted by elevated medial PFC and right inferior frontal gyrus 
activity.  While PFC has been strongly linked to response inhibition, it subserves this cognitive 
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ability as a part of a larger cerebral network [23], hence focusing on this region only may constitute a 
major limitation of this study.   
Strikingly, there is only one report of alterations in frontolimbic circuitry under TFP, which suggests 
that the mechanism by which the treatment achieves change involves increased activity within dorsal 
prefrontal areas (dorsal ACC, dlPFC, and frontopolar cortices), and decreased ventrolateral PFC and 
hippocampus activation [95].  In addition, pre- TFP hypoactivation in the right dorsal ACC predicted 
post- treatment improvements in constraint, whereas pre-treatment hypoactivation in the left 
posterior-medial OFC/ventral striatum hypoactivation was associated with amelioration in affective 
lability.  Finally, one study supports that the therapeutic action of OXT occurs via reducing amygdala 
activation, which optimizes reflexive processing of social cues and modulates the salience of social 
information [100].  The strongest effects were observed in the posterior part of the amygdala, 
presumably correspond to the basal nucleus involved in assigning salience to negative facial 
expressions and in redirecting attention toward socially pertinent locations within visual field 
[101,102].  However, as no clinical group was included in the study, caution must be exercised while 
drawing borderline- specific conclusions.  
Conclusion  
The past decade of neuroimaging research has helped to elucidate some key processes that BPD 
treatments entail at brain level to achieve therapeutic change. Evidence suggests that successful DBT 
alters neural underpinnings of emotion regulation, TFP downregulates key neural circuits of 
impulsivity, and OXT attenuates amygdala activation, and therefore optimizes reflexive processing 
of social information. These findings allow to speculate that different therapeutic models are unlikely 
to have a specific neural mechanism of action.  Taken together, evidence shows that treatment- 
induced neural recovery from BPD occurs via downregulation of neuronal activity within limbic 
regions, including the insula and amygdala, together with differential employment of prefrontal 
areas, mainly OFC, ACC and dlPFC, as well as enhanced functional connectivity between limbic and 
prefrontal regions.  Although preliminary evidence is limited by the pilot nature of studies, low 
power, small sample size and generalizability issues, statistically significant results warrant future 
efforts to disentangle key neural circuits behind treatment processes to refine strategies for specific 
symptoms. Understanding how various treatments achieve their therapeutic effects on neural 
functioning will not only advance the empirical status of evidence- based treatments, but might also 





Future studies on treatment- induced bran plasticity in BPD should disentangle key neural circuits 
underlying variety of treatments for which evidence of efficacy has been demonstrated:  
- Apart from DBT, brain changes under other established evidence based treatment should be 
examined, namely Mentalization- Based treatment (MBT), Transference- Focus 
psychotherapy (TFP), Schema- Focused therapy (SFT) and systems training for emotional 
predictability and problem solving (STEPPS)  
- Further research is warranted to reconcile mixed results, and to answer the remaining 
questions on the use of OXT in BPD treatment. 
- Novel drugs such as opioid antagonist, clonidine, omega- 3 fatty acids, have demonstrated 
efficacy in reducing affective instability, impulsivity, self - injuries, and dissociative 
symptoms and therefore should be the focus of future research on treatment- induced brain 
plasticity.  
 
Executive Summary  
 
1. Introduction 
 Although neural substrates of symptoms expression in Borderline Personality Disorder (BPD) 
have been studied extensively, neural mechanisms of post treatment amelioration of 
symptoms remain poorly understood.  
 This review sheds a critical light on all here-to-date fMRI findings of brain changes in BPD 
patients following a treatment with psychotherapy or drugs.  
 Publications until October 2017 were selected through systematic literature search or 
identified manually by searching reference lists of selected articles.  
2. Review of fMRI studies  
 Eight studies of treatment- induced brain plasticity were identified, six focusing on 
Dialectical Behavioural Therapy (DBT), one on Transference-Focused psychotherapy (TFP), 
and one on Oxytocin (OXT). 
 
2.1. fMRI studies of DBT effects 
 Preliminary evidence suggests that neural underpinnings of emotion regulation in BPD may 
change under DBT.   
 This was reflected in downregulation of neuronal activity within limbic regions, including the 
insula and amygdala, together with differential employment of prefrontal areas, mainly OFC, 




2.2. fMRI study of TFP effects 
 TFP induced elevated dorsal prefrontal activity during go/no-go paradigm, which might 
indicate key neural circuits of impulsivity.   
2.3. fMRI studies of oxytocin effects 
 Oxytonergic effects on facial threat processing was reflected in reduced activation of the 
amygdala, thereby optimizing reflexive processing of social cues and modulating the salience 
of social information. 
3. Discussion 
 Preliminary evidence suggests that neural underpinnings of emotion regulation in BPD may 
change under DBT 
 Evidence, albeit limited by the pilot nature of studies, low power, small sample size and 
generalizability issues, warrant future efforts to disentangle key neural circuits underlying 
treatment processes. 
 Knowing how various treatments achieve their therapeutic effects on the level of brain 
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